High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
10.97B
+10.98%
6.218
+6.11%
11.03B
+6.69%
6.234
+3.73%
11.19B
+6.56%
5.987
+18.56%
Estimates Revision
The market is revising Upward the revenue expectations for Molina Healthcare, Inc. (MOH) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by -6.20%.
Revenue Estimates for FY2025
Revise Upward
+0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.25%
In Past 3 Month
Stock Price
Go Down
-6.20%
In Past 3 Month
11 Analyst Rating
0Wall Street analysts forecast MOH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOH is 370.60 USD with a low forecast of 309.00 USD and a high forecast of 414.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
1 Sell
Moderate Buy
0Current: 295.340
Low
309.00
Averages
370.60
High
414.00
0Current: 295.340
Low
309.00
Averages
370.60
High
414.00
Morgan Stanley
Erin Wright
Overweight
initiated
$364
2025-06-09
Reason
Morgan Stanley
Erin Wright
Price Target
$364
2025-06-09
initiated
Overweight
Reason
Morgan Stanley analyst Erin Wright initiated coverage of Molina Healthcare with an Overweight rating and $364 price target. While "varying permutations of policy headwinds are looming" across Medicaid, the overhang is disproportionately reflected in Molina at "trough valuations," the analyst tells investors in a research note. The firm sees a strengthening Medicaid footprint and dual eligible integration potential for the company. Policy risk is a key variable but could be more manageable than feared, contends Morgan Stanley. While the Medicaid sector is not without risk, the overhangs are largely reflected in valuations at 10-year troughs, on average, contends the firm.
Barclays
Equal Weight
downgrade
$351 -> $347
2025-06-09
Reason
Barclays
Price Target
$351 -> $347
2025-06-09
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Molina Healthcare to $347 from $351 and keeps an Equal Weight rating on the shares.
Barclays
Equal Weight
downgrade
$362 -> $351
2025-06-02
Reason
Barclays
Price Target
$362 -> $351
2025-06-02
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on Molina Healthcare to $351 from $362 and keeps an Equal Weight rating on the shares. Following Q1 earnings and "several negative data points" around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Barclays
Equal Weight
maintain
$339 -> $362
2025-04-25
Reason
Barclays
Price Target
$339 -> $362
2025-04-25
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Molina Healthcare to $362 from $339 and keeps an Equal Weight rating on the shares following the Q1 report.
TD Cowen
Buy
maintain
$342 -> $369
2025-04-25
Reason
TD Cowen
Price Target
$342 -> $369
2025-04-25
maintain
Buy
Reason
TD Cowen raised the firm's price target on Molina Healthcare to $369 from $342 and keeps a Buy rating on the shares. The firm updated its model following Q1 results.
Bernstein
Lance Wilkes
Buy
Initiates
$414
2025-04-22
Reason
Bernstein
Lance Wilkes
Price Target
$414
2025-04-22
Initiates
Buy
Reason
Bernstein initiated coverage of Molina Healthcare with an Outperform rating and $414 price target, representing 28% upside. The firm believes the near and long term outlook for Medicaid is attractive, but says policy uncertainty exists over the coming months through Reconciliation. Molina is an effective competitor and will grow above sector rates, the analyst tells investors in a research note. Bernstein sees improving near term margins in Medicaid, coupled with long term growth potential.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Molina Healthcare Inc (MOH.N) is 11.72, compared to its 5-year average forward P/E of 15.54. For a more detailed relative valuation and DCF analysis to assess Molina Healthcare Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
15.54
Current PE
11.72
Overvalued PE
17.72
Undervalued PE
13.35
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Undervalued
5Y Average EV/EBITDA
9.12
Current EV/EBITDA
7.20
Overvalued EV/EBITDA
10.37
Undervalued EV/EBITDA
7.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
0.52
Current PS
0.36
Overvalued PS
0.59
Undervalued PS
0.45
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
MOH News & Events
Events Timeline
(ET)
2025-06-16
16:31:35
Senate Republicans abandon Medicare cost cuts, Bloomberg reports
2025-06-05 (ET)
2025-06-05
14:06:21
Senate Republicans consider Medicare spending cuts, Bloomberg says
2025-06-04 (ET)
2025-06-04
06:10:27
Trump conceals Medicaid cuts in effort to pass major tax bill, Bloomberg says
Sign Up For More Events
Sign Up For More Events
News
Preview
4.5
06-17NASDAQ.COMStocks Settle Higher on Possible De-Escalation of Israel-Iran War
Preview
8.0
06-17SeekingAlphaSenate GOP tax bill is said to target key Medicaid provision, omit Medicare cuts
Preview
4.5
06-16NASDAQ.COMStocks Rebound on Hopes Israel-Iran Conflict Will be Contained
Sign Up For More News
People Also Watch
FAQ
What is Molina Healthcare Inc (MOH) stock price today?
What is Molina Healthcare Inc (MOH)'s business?
What is the price predicton of MOH Stock?
What is Molina Healthcare Inc (MOH)'s revenue for the last quarter?
What is Molina Healthcare Inc (MOH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Molina Healthcare Inc (MOH)'s fundamentals?
How many employees does Molina Healthcare Inc (MOH). have?